Folgen
Nadeem Riaz
Titel
Zitiert von
Zitiert von
Jahr
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
24892019
Tumor and microenvironment evolution during immunotherapy with nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ...
Cell 171 (4), 934-949. e16, 2017
14122017
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
VP Balachandran, M Łuksza, JN Zhao, V Makarov, JA Moral, R Remark, ...
Nature 551 (7681), 512-516, 2017
8462017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
8452018
Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a …
B O'Sullivan, SH Huang, J Su, AS Garden, EM Sturgis, K Dahlstrom, ...
The Lancet Oncology 17 (4), 440-451, 2016
6742016
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a …
C Luchini, F Bibeau, MJL Ligtenberg, N Singh, A Nottegar, T Bosse, ...
Annals of Oncology 30 (8), 1232-1243, 2019
5922019
The head and neck cancer immune landscape and its immunotherapeutic implications
R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel, MG Dalin, N Riaz, ...
JCI insight 1 (17), 2016
5702016
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ...
Nature 551 (7681), 517-520, 2017
5142017
Mitochondrial DNA copy number variation across human cancers
E Reznik, ML Miller, Y Şenbabaoğlu, N Riaz, J Sarungbam, SK Tickoo, ...
elife 5, e10769, 2016
3892016
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ...
Science 364 (6439), 485-491, 2019
3662019
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
G Goh, T Walradt, V Markarov, A Blom, N Riaz, R Doumani, K Stafstrom, ...
Oncotarget 7 (3), 3403, 2016
3422016
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung CancerSLFN11 Predicts PARP Inhibitor Response in SCLC
BH Lok, EE Gardner, VE Schneeberger, A Ni, P Desmeules, N Rekhtman, ...
Clinical Cancer Research 23 (2), 523-535, 2017
2662017
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
LGT Morris, N Riaz, A Desrichard, Y Şenbabaoğlu, AA Hakimi, V Makarov, ...
Oncotarget 7 (9), 10051-10063, 2016
2582016
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
W Yang, KW Lee, RM Srivastava, F Kuo, C Krishna, D Chowell, ...
Nature medicine 25 (5), 767-775, 2019
2412019
Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma
S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ...
Journal of Clinical Oncology 39 (1), 30, 2021
2002021
The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform
LGT Morris, R Chandramohan, L West, A Zehir, D Chakravarty, DG Pfister, ...
JAMA oncology 3 (2), 244-255, 2017
1962017
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
YP Chen, YQ Wang, JW Lv, YQ Li, MLK Chua, QT Le, N Lee, AD Colevas, ...
Annals of Oncology 30 (1), 68-75, 2019
1952019
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
N Riaz, P Blecua, RS Lim, R Shen, DS Higginson, N Weinhold, L Norton, ...
Nature communications 8 (1), 857, 2017
1922017
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
D Chowell, C Krishna, F Pierini, V Makarov, NA Rizvi, F Kuo, LGT Morris, ...
Nature medicine 25 (11), 1715-1720, 2019
1762019
Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes
I Ganly, V Makarov, S Deraje, YY Dong, E Reznik, V Seshan, ...
Cancer Cell 34 (2), 256-270. e5, 2018
1752018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20